Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination With Induction Therapy and Consolidation Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 and/or IDH2 Mutation

NCT02632708 is registered in ClinicalTrials.gov with Institut de Recherches Internationales Servier as lead sponsor.

NCT NCT02632708
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02632708 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination With Induction Therapy and Consolidation Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 and/or IDH2 Mutation
Lead sponsor
Institut de Recherches Internationales Servier
Phase
Phase 1
Overall status
Active, not recruiting
Start date
December 31, 2015
Completion date
July 24, 2026
Enrollment
153 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

aml arising after exposure to genotoxic injury, aml arising from antecedent hematologic disorder (ahd), aml arising from myelodysplastic syndrome (mds), newly diagnosed acute myeloid leukemia (aml), untreated aml